U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with hemophilia A or B

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: August 2021

Workgroups: Blood Disorders and Blood Safety Workgroup

In this Cochrane systematic review, researchers found that preventive treatment with clotting factor concentrates may reduce the number of joint bleeds in people with hemophilia who have previously been treated for joint bleeding. This may lead to an improvement in joint function, pain, and quality of life. However, further research is needed to determine the best starting time, frequency, and dose of preventive treatment.

Read more about this resource

Objectives related to this resource (1)

Reduce the proportion of people with severe hemophilia who have more than 4 joint bleeds each year — BDBS‑01
Target met or exceeded

Suggested Citation

1.

Olasupo, O. O., Lowe, M. S., Krishan, A., Collins, P., Iorio, A. & Matino, D. (2021). Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B, 2021 (8). DOI: 10.1002/14651858.CD014201.